Literature DB >> 12768126

Modeling the two-hit hypothesis for evaluating strategies to prevent organ injury after shock/resuscitation.

Ori D Rotstein1.   

Abstract

The major cause of late death in patients sustaining major trauma relates to the development of progressive organ failure. Recent studies suggest that trauma victims are rendered susceptible to the development of organ failure because antecedent shock/resuscitation renders them susceptible to an exaggerated immune response to late inflammatory stimuli, the so-called two-hit hypothesis. In this article, the rationale underlying the use of a "two-hit" model in trauma research is reviewed and a specific example is cited. Importantly, these models permit investigation aimed at understanding the cellular and molecular mechanisms of disease after shock/resuscitation. Interventions such as antioxidant therapy and hypertonic saline resuscitation have a rational basis for use and have been shown to be effective in a rodent two-hit lung injury model. These studies suggest potential use in the critically ill trauma patient population.

Entities:  

Mesh:

Year:  2003        PMID: 12768126     DOI: 10.1097/01.TA.0000064512.62949.92

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  29 in total

1.  One-hit, two-hit . . . is there really any benefit?

Authors:  J D Lang; J M Hickman-Davis
Journal:  Clin Exp Immunol       Date:  2005-08       Impact factor: 4.330

2.  The immunomodulatory effects of hypertonic saline resuscitation in patients sustaining traumatic hemorrhagic shock: a randomized, controlled, double-blinded trial.

Authors:  Sandro B Rizoli; Shawn G Rhind; Pang N Shek; Kenji Inaba; Dennis Filips; Homer Tien; Fred Brenneman; Ori Rotstein
Journal:  Ann Surg       Date:  2006-01       Impact factor: 12.969

3.  Histone deacetylase inhibitor treatment attenuates MAP kinase pathway activation and pulmonary inflammation following hemorrhagic shock in a rodent model.

Authors:  Ashley R Kochanek; Eugene Y Fukudome; Yongqing Li; Eleanor J Smith; Baoling Liu; George C Velmahos; Marc deMoya; David King; Hasan B Alam
Journal:  J Surg Res       Date:  2011-07-05       Impact factor: 2.192

4.  Hypertonic saline resuscitation maintains a more balanced profile of T-lymphocyte subpopulations in a rat model of hemorrhagic shock.

Authors:  Yuan-qiang Lu; Xiu-jun Cai; Lin-hui Gu; Han-zhou Mu; Wei-dong Huang
Journal:  J Zhejiang Univ Sci B       Date:  2007-01       Impact factor: 3.066

5.  Neutrophils counteract autophagy-mediated anti-inflammatory mechanisms in alveolar macrophage: role in posthemorrhagic shock acute lung inflammation.

Authors:  Zongmei Wen; Liyan Fan; Yuehua Li; Zui Zou; Melanie J Scott; Guozhi Xiao; Song Li; Timothy R Billiar; Mark A Wilson; Xueyin Shi; Jie Fan
Journal:  J Immunol       Date:  2014-09-29       Impact factor: 5.422

6.  Lower tidal volumes for everyone: principle or prescription?

Authors:  John J Marini
Journal:  Intensive Care Med       Date:  2012-11-21       Impact factor: 17.440

Review 7.  Alarmins: awaiting a clinical response.

Authors:  James K Chan; Johannes Roth; Joost J Oppenheim; Kevin J Tracey; Thomas Vogl; Marc Feldmann; Nicole Horwood; Jagdeep Nanchahal
Journal:  J Clin Invest       Date:  2012-08-01       Impact factor: 14.808

8.  The protective effects of glutamine in a rat model of ventilator-induced lung injury.

Authors:  Chin-Ming Chen; Kuo-Chen Cheng; Chien-Feng Li; Haibo Zhang
Journal:  J Thorac Dis       Date:  2014-12       Impact factor: 2.895

9.  L-arginine infusion during resuscitation for hemorrhagic shock: impact and mechanism.

Authors:  Tania K Arora; Ajai K Malhotra; Rao Ivatury; Martin J Mangino
Journal:  J Trauma Acute Care Surg       Date:  2012-02       Impact factor: 3.313

10.  Protective effects of adenosine A2A receptor agonist in ventilator-induced lung injury in rats.

Authors:  Chin-Ming Chen; Oscar Penuelas; Kieran Quinn; Kuo-Chen Cheng; Chien-Feng Li; Haibo Zhang; Arthur S Slutsky
Journal:  Crit Care Med       Date:  2009-07       Impact factor: 7.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.